Cost of Revenue Comparison: Viatris Inc. vs Xencor, Inc.

A Tale of Two Companies: Viatris Inc. vs Xencor, Inc.

In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. Viatris Inc. and Xencor, Inc. offer a fascinating study in contrasts. Over the past decade, Viatris has consistently reported a cost of revenue that dwarfs Xencor's, with Viatris's costs peaking in 2021 at over 12 times its 2014 figures. Meanwhile, Xencor's cost of revenue, though significantly smaller, has shown a steady upward trend, culminating in a 2023 figure that is nearly 14 times its 2014 cost.

Key Insights

• Viatris Inc.: From 2014 to 2023, Viatris's cost of revenue increased by approximately 122%, reflecting its expansive operations.
• Xencor, Inc.: Despite its smaller scale, Xencor's cost of revenue surged by about 1,270% over the same period, indicating rapid growth.

This comparison highlights the diverse strategies and growth trajectories within the pharmaceutical industry.